Capricor Therapeutics, Inc. (CAPR): EBITDA
-$106.25M
Year ended 2025-12-31
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$106.25M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$41.14M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$23.01M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$29.16M | n/m | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | -$20.69M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$13.55M | n/m | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | -$7.56M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$15.17M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$12.72M | n/m | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | -$16.85M | n/m | 2018-03-22, From 2016-01-01 |
| 2015-12-31 | -$12.50M | n/m | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | -$5.98M | n/m | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | -$6.88M | n/m | 2015-03-16, From 2013-01-01 |
| 2012-12-31 | -$2.08M | n/c | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | -$4.89M | n/m | 2013-06-21, From 2011-01-01 |
| 2010-12-31 | -$6.28M | n/a | 2012-04-02, From 2010-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | -$106.25M | n/m |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.01M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $38.59M | +12.5% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.06M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$224.0K | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $3.16B | +317.9% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $270.0K | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | -$21.57M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $8.87M | -42.2% |
Compare CAPR, TXMD, NATR, LSTA side by side · Screen every company in Pharmaceutical Preparations ↗